Please use this link to access this publication. Abstract Purpose of Review There are disproportionately elevated rates of cannabis use and cannabis use disorder (CUD) among sexual and gender minoritized (SGM) individuals. Minority stressors (e.g., victimization, internalized stigma) are a robust predictor of SGM cannabis and related outcomes. The psychological mediation framework posits that changes in coping and emotion regulation, social/interpersonal, cognitive, and SGM group-specific functioning explain associations between minority stress and cannabis outcomes. This systematic review covers the extant literature evaluating the putative mechanisms that link minority stress to cannabis use and related outcomes. Recent Findings Searches were conducted on MEDLINE, Embase, PsycInfo,...

Please use this link to access this publication. Abstract Since cannabis and nicotine are two of most commonly used substances and are often used together, this paper will review the effects of cannabis (specifically THC, or tetrahydrocannabinol) and nicotine on selective attention, sustained attention, visuospatial attention, attentional bias, and attentional disorders. This review includes preclinical and clinical findings throughout all periods of development and adulthood. Selective attention is directly impacted by cannabis use, while reaction time is dependent on the timing of the last cannabis exposure. Among individuals who use cannabis, there is an attentional bias that reduces anxiety and increases focus on cannabis-related...

Abstract Thromboangiitis obliterans (TAO) is an inflammatory vasculopathy that often presents in young men with substantial tobacco use. Cannabis arteritis is the cannabis-associated counterpart, but there remains controversy over its classification due to overwhelming concurrent tobacco use. A 31-year-old man developed lifestyle-limiting claudication that coincided with vaping high-potency tetrahydrocannabinol. Notably, his tobacco exposure was limited to a remote history of <1 pack-year. His claudication considerably improved after 4 weeks of cannabis cessation. This case demonstrates a rare instance of cannabis arteritis without concurrent tobacco use, suggesting cannabis may act as an independent causative agent of a distinct thromboangiitis obliterans-like arteritis.

Please use this link to access this publication. Abstract Introduction: Aromatase inhibitors (AIs) are commonly used for postmenopausal women with hormone receptor-positive breast cancer. Nearly two-thirds of women on AIs have arthralgias, joint stiffness, and/or bone pains referred to as aromatase inhibitor-induced musculoskeletal syndrome (AIMSS), leading to poor adherence. Preclinical and clinical data suggest topical cannabinoids can reduce inflammation in arthritis. Materials and Methods: We conducted a randomized trial assessing feasibility, tolerability, and preliminary efficacy of topical cannabis for women with stage 1–3 breast cancer experiencing AIMSS. Women were randomized 1:1 to cannabidiol (CBD) vs. delta-9-tetrahydrocannabinol (THC) balms. The balm was applied three times daily to...

Please use this link to access this publication. Abstract Novel methods of cannabis use are becoming popular, but the differential impact of these new methods on cognition have not been widely studied. Further, the impact of cannabis on cognition is mediated by delta-9-tetrahydrocannabinol (THC), but few studies have directly compared the pharmacokinetics of different methods. This systematic review (PROSPERO, CRD42023442731) was conducted to determine whether the different forms of cannabis and routes of administration have differential acute effects on cognition or blood THC. In total, six studies were found that directly compared the effects of at least two different methods of cannabis administration on cognition and eight studies compared the impact...

Please use this link to access this publication. Abstract Background: Rapid changes in the legalized cannabis market have led to the predominance of high-concentration delta-9-tetrahydrocannabinol (THC) cannabis products. Purpose: To systematically review associations of high-concentration THC cannabis products with mental health outcomes. Data Sources: Ovid MEDLINE through May 2025; EMBASE, Allied and Complementary Medicine Database, Cochrane Library, Database of Abstracts of Reviews of Effects, CINAHL, and Toxicology Literature Online through August 2024. Study Selection: Two reviewers independently selected studies with high-concentration THC defined as greater than 5 mg or greater than 10% THC per serving or labeled as “high-potency concentrate,” “shatter,” or “dab.” Data...

ABSTRACT With the partial legalization of high-THC Cannabis sativa across 23 states for recreational use and 38 states for medical purposes in the United States, the Cannabis industry is poised for significant growth. Projected to reach a sales volume of $50.7 billion by 2028, this growth is driven by the trend of lifting Cannabis prohibition. High-THC C. sativa cultivars, containing more than 0.3% delta-9 tetrahydrocannabinol (Δ9-THC) as defined by the 2018 US Farm Bill, are used for both medicinal and recreational purposes. Cannabis sativa is a short day, dioecious, annual plant, where female plants are favored for THC production, which requires seed feminization techniques to ensure an accurate female plant population. This involves using...

Abstract Cannabis has been used to relieve the symptoms of disease for thousands of years. However, social and political biases have limited effective interrogation of the potential benefits of cannabis and polarised public opinion. Further, the medicinal and clinical utility of cannabis is limited by the psychotropic side effects of ∆9-tetrahydrocannabinol (∆9-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that ∆9-THC can inhibit the growth and...

Abstract Cannabidiol (CBD) is a naturally occurring, non-psychotropic cannabinoid of the hemp plant Cannabis sativa L. and has been known to induce several physiological and pharmacological effects. While CBD is approved as a medicinal product subject to prescription, it is also widely sold over the counter (OTC) in the form of food supplements, cosmetics and electronic cigarette liquids. However, regulatory difficulties arise from its origin being a narcotic plant or its status as an unapproved novel food ingredient. Regarding the consumer safety of these OTC products, the question whether or not CBD might be degraded into psychotropic cannabinoids, most prominently tetrahydrocannabinol (THC), under in vivo conditions...

Abstract Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has been approved to treat symptoms of spasticity. In animals, CBD is effective in reducing the amounts of T-cell infiltrates in the spinal cord, suggesting CBD has anti-inflammatory properties. By doing this, CBD has shown to delay symptom onset in animal models of multiple sclerosis and slow disease progression. Importantly, combinations of CBD and Δ9-THC appear more effective in treating animal models of multiple sclerosis. While CBD reduces the amounts...